Zafgen Stock Price, News & Analysis (NASDAQ:ZFGN)

$8.37 +0.24 (+2.95 %)
(As of 02/20/2018 02:58 AM ET)
Previous Close$8.13
Today's Range$8.11 - $8.48
52-Week Range$3.21 - $9.36
Volume200,700 shs
Average Volume237,245 shs
Market Capitalization$230.09 million
P/E Ratio-4.62
Dividend YieldN/A
Beta-0.51

About Zafgen (NASDAQ:ZFGN)

Zafgen logoZafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003

Debt

Debt-to-Equity RatioN/A
Current Ratio13.61%
Quick Ratio13.61%

Price-To-Earnings

Trailing P/E Ratio-4.62428384373567
Forward P/E Ratio-4.14
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.45 per share
Price / Book1.88

Profitability

Trailing EPS($1.81)
Net Income$-57,870,000.00
Net MarginsN/A
Return on Equity-46.88%
Return on Assets-43.31%

Miscellaneous

Employees32
Outstanding Shares27,490,000

Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.12. View Zafgen's Earnings History.

When will Zafgen make its next earnings announcement?

Zafgen is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Zafgen.

Where is Zafgen's stock going? Where will Zafgen's stock price be in 2018?

2 brokerages have issued twelve-month price targets for Zafgen's stock. Their forecasts range from $9.00 to $9.00. On average, they expect Zafgen's share price to reach $9.00 in the next twelve months. View Analyst Ratings for Zafgen.

Who are some of Zafgen's key competitors?

Who are Zafgen's key executives?

Zafgen's management team includes the folowing people:

  • Peter Barrett Ph.D., Independent Chairman of the Board (Age 64)
  • Thomas E. Hughes Ph.D., President, Chief Scientific Officer, Director (Age 57)
  • Jeffrey S. Hatfield, Chief Executive Officer, Director
  • Patricia L. Allen CPA, Chief Financial Officer (Age 54)
  • Dennis D. Kim M.D., Chief Medical Officer (Age 46)
  • Bruce L. Booth Ph.D., Director (Age 42)
  • Thomas O. Daniel M.D., Director (Age 63)
  • Geoffrey McDonough M.D., Director (Age 47)
  • Robert J. Perez, Director (Age 52)
  • Frances K. Heller J.D., Independent Director (Age 49)

Who owns Zafgen stock?

Zafgen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (3.40%), Renaissance Technologies LLC (2.44%), Mangrove Partners (2.14%), Royce & Associates LP (2.00%), AWM Investment Company Inc. (1.46%) and Deutsche Bank AG (0.81%). Company insiders that own Zafgen stock include Dennis D Kim, Frances K Heller, Patricia L Allen and Thomas E Hughes. View Institutional Ownership Trends for Zafgen.

Who sold Zafgen stock? Who is selling Zafgen stock?

Zafgen's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Deutsche Bank AG, Spark Investment Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Zafgen.

Who bought Zafgen stock? Who is buying Zafgen stock?

Zafgen's stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, AWM Investment Company Inc., Royce & Associates LP, Nexthera Capital LP, Bank of New York Mellon Corp, Two Sigma Investments LP, Mangrove Partners and Acadian Asset Management LLC. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim, Frances K Heller, Patricia L Allen and Thomas E Hughes. View Insider Buying and Selling for Zafgen.

How do I buy Zafgen stock?

Shares of Zafgen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zafgen's stock price today?

One share of Zafgen stock can currently be purchased for approximately $8.37.

How big of a company is Zafgen?

Zafgen has a market capitalization of $230.09 million. The biopharmaceutical company earns $-57,870,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis. Zafgen employs 32 workers across the globe.

How can I contact Zafgen?

Zafgen's mailing address is 175 PORTLAND STREET 4TH FLOOR, BOSTON MA, 02114. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]


MarketBeat Community Rating for Zafgen (ZFGN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zafgen (NASDAQ:ZFGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.502.502.502.33
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.00$34.50
Price Target Upside: 83.67% upside83.67% upside83.67% upside604.08% upside

Zafgen (NASDAQ:ZFGN) Consensus Price Target History

Price Target History for Zafgen (NASDAQ:ZFGN)

Zafgen (NASDAQ:ZFGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2017Roth CapitalInitiated CoverageBuy -> Buy$9.00HighView Rating Details
3/10/2017CowenReiterated RatingHoldN/AView Rating Details
3/7/2017FBR & CoReiterated RatingMarketperformLowView Rating Details
7/21/2016Canaccord GenuitySet Price TargetHold$7.00 -> $4.00N/AView Rating Details
7/20/2016Leerink SwannReiterated RatingMarket Perform$6.00N/AView Rating Details
4/5/2016Royal Bank of CanadaReiterated RatingOutperform$19.00N/AView Rating Details
2/20/2016SunTrust BanksReiterated RatingHold$7.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Zafgen (NASDAQ:ZFGN) Earnings History and Estimates Chart

Earnings by Quarter for Zafgen (NASDAQ:ZFGN)

Zafgen (NASDAQ ZFGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.56)N/AView Earnings Details
11/7/2017Q3 2017($0.58)($0.46)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.52)($0.49)ViewListenView Earnings Details
5/9/2017Q1 2017($0.43)($0.48)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.50)($0.38)ViewListenView Earnings Details
11/9/2016Q3 2016($0.65)($0.54)ViewN/AView Earnings Details
8/4/2016Q2 2016($0.67)($0.55)ViewN/AView Earnings Details
5/10/2016Q116($0.74)($0.65)ViewListenView Earnings Details
3/9/2016Q415($0.80)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.79)($0.73)$80.60 million$78.20 millionViewListenView Earnings Details
8/11/2015Q215($0.71)($0.66)ViewListenView Earnings Details
5/12/2015Q115($0.52)($0.53)ViewListenView Earnings Details
3/19/2015Q414($0.84)($0.48)ViewListenView Earnings Details
11/11/2014Q314($0.87)($0.65)ViewN/AView Earnings Details
8/13/2014Q214($0.28)($2.96)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Zafgen (NASDAQ:ZFGN) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.02 EPS
Next Year EPS Consensus Estimate: $-1.35 EPS

Dividends

Dividend History for Zafgen (NASDAQ:ZFGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Zafgen (NASDAQ ZFGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.20%
Institutional Ownership Percentage: 50.82%
Insider Trades by Quarter for Zafgen (NASDAQ:ZFGN)
Insider Trades by Quarter for Zafgen (NASDAQ:ZFGN)

Zafgen (NASDAQ ZFGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/13/2017Frances K HellerDirectorBuy10,000$3.90$39,000.00View SEC Filing  
7/11/2017Dennis D KimInsiderBuy10,000$3.39$33,900.0021,443View SEC Filing  
5/11/2017Dennis D. KimInsiderBuy10,000$4.40$44,000.00View SEC Filing  
12/19/2016Frances K HellerDirectorBuy10,000$3.23$32,300.0030,000View SEC Filing  
11/15/2016Frances K HellerDirectorBuy10,000$3.54$35,400.0020,000View SEC Filing  
8/29/2016Thomas E HughesInsiderBuy10,000$3.00$30,000.0063,936View SEC Filing  
7/26/2016Patricia L. AllenCFOBuy16,000$3.12$49,920.00View SEC Filing  
7/22/2016Frances K HellerDirectorBuy10,000$2.99$29,900.0010,000View SEC Filing  
7/22/2016Thomas E. HughesInsiderBuy5,000$3.02$15,100.00View SEC Filing  
2/12/2016James E FlynnInsiderBuy64,545$6.25$403,406.25View SEC Filing  
2/11/2016James E FlynnInsiderBuy267,493$6.02$1,610,307.86View SEC Filing  
9/24/2015Kevin P StarrDirectorSell136,579$43.90$5,995,818.10370,323View SEC Filing  
9/18/2015Avi Y GoldbergDirectorSell5,000$45.00$225,000.0053,734View SEC Filing  
9/18/2015Thomas E. HughesCEOSell45,626$42.53$1,940,473.78820View SEC Filing  
9/17/2015Dennis D. KiminsiderSell39,407$40.00$1,576,280.00View SEC Filing  
6/10/2015Avi Y GoldbergDirectorSell3,000$35.00$105,000.00View SEC Filing  
6/1/2015Avi Y GoldbergDirectorSell2,000$32.23$64,460.00View SEC Filing  
6/19/2014Alicia SecorInsiderBuy4,000$20.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zafgen (NASDAQ ZFGN) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Zafgen Inc (ZFGN) to Announce -$0.59 Earnings Per Share Brokerages Anticipate Zafgen Inc (ZFGN) to Announce -$0.59 Earnings Per Share
www.americanbankingnews.com - February 18 at 12:08 PM
Zafgen (ZFGN) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowZafgen (ZFGN) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 15 at 5:02 PM
Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceZafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 9:38 AM
Zafgen (ZFGN) Raised to Sell at ValuEngineZafgen (ZFGN) Raised to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 6:52 AM
Zymeworks (ZYME) and Zafgen (ZFGN) Financial ContrastZymeworks (ZYME) and Zafgen (ZFGN) Financial Contrast
www.americanbankingnews.com - January 17 at 9:14 PM
Zafgen (ZFGN) Downgraded to "Hold" at Zacks Investment ResearchZafgen (ZFGN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 13 at 4:08 PM
Blog Exposure - Zafgen Reports Strong Clinical Progress and Updates OutlookBlog Exposure - Zafgen Reports Strong Clinical Progress and Updates Outlook
finance.yahoo.com - January 8 at 10:43 AM
Zafgen (ZFGN) Announces Strong Clinical Progress and Updates Outlook for 2018Zafgen (ZFGN) Announces Strong Clinical Progress and Updates Outlook for 2018
www.streetinsider.com - January 6 at 10:32 AM
BRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount Of $20 MlnBRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount Of $20 Mln
www.reuters.com - January 6 at 10:32 AM
Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018  Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018  
finance.yahoo.com - January 5 at 10:48 AM
-$0.59 Earnings Per Share Expected for Zafgen Inc (ZFGN) This Quarter-$0.59 Earnings Per Share Expected for Zafgen Inc (ZFGN) This Quarter
www.americanbankingnews.com - December 29 at 3:22 PM
Zafgen, Inc. (ZFGN) Receives Average Rating of "Hold" from AnalystsZafgen, Inc. (ZFGN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - December 15 at 3:54 PM
-$0.59 EPS Expected for Zafgen, Inc. (ZFGN) This Quarter-$0.59 EPS Expected for Zafgen, Inc. (ZFGN) This Quarter
www.americanbankingnews.com - December 12 at 11:36 AM
Zafgen, Inc. (ZFGN) Expected to Announce Earnings of -$0.59 Per ShareZafgen, Inc. (ZFGN) Expected to Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - November 24 at 1:18 PM
Zafgen, Inc. (ZFGN) Receives Average Recommendation of "Hold" from AnalystsZafgen, Inc. (ZFGN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 20 at 3:46 PM
Zacks Investment Research Upgrades Zafgen, Inc. (ZFGN) to "Buy"Zacks Investment Research Upgrades Zafgen, Inc. (ZFGN) to "Buy"
www.americanbankingnews.com - November 11 at 10:22 AM
Leerink Swann Comments on Zafgen, Inc.s FY2017 Earnings (ZFGN)Leerink Swann Comments on Zafgen, Inc.'s FY2017 Earnings (ZFGN)
www.americanbankingnews.com - November 10 at 12:26 PM
Zafgen, Inc. (ZFGN) Announces Quarterly  Earnings Results, Beats Expectations By $0.12 EPSZafgen, Inc. (ZFGN) Announces Quarterly Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - November 8 at 7:11 PM
Zafgen Reports Third Quarter 2017 Financial ResultsZafgen Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 9:28 PM
Zafgen reports 3Q lossZafgen reports 3Q loss
finance.yahoo.com - November 7 at 9:28 PM
Head to Head Contrast: Zafgen (ZFGN) & Its RivalsHead to Head Contrast: Zafgen (ZFGN) & Its Rivals
www.americanbankingnews.com - November 1 at 3:12 AM
Zafgen, Inc. (ZFGN) Set to Announce Quarterly Earnings on TuesdayZafgen, Inc. (ZFGN) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:52 AM
Financial Contrast: Zafgen (ZFGN) versus Its CompetitorsFinancial Contrast: Zafgen (ZFGN) versus Its Competitors
www.americanbankingnews.com - October 30 at 11:40 AM
Zafgen Inc (ZFGN) Receives Average Rating of "Hold" from BrokeragesZafgen Inc (ZFGN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 26 at 5:48 PM
Zafgen, Inc. (ZFGN) Director Acquires $39,000.00 in StockZafgen, Inc. (ZFGN) Director Acquires $39,000.00 in Stock
www.americanbankingnews.com - October 17 at 8:18 PM
Zafgen, Inc. (ZFGN) Rating Lowered to Hold at Zacks Investment ResearchZafgen, Inc. (ZFGN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 14 at 5:52 PM
Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - October 13 at 10:35 AM
Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - October 13 at 10:35 AM
Zafgen (ZFGN) Announces Jeffrey Hatfield as New CEO; Thomas Hughes to Remain President, Assume Chief ... - StreetInsider.comZafgen (ZFGN) Announces Jeffrey Hatfield as New CEO; Thomas Hughes to Remain President, Assume Chief ... - StreetInsider.com
www.streetinsider.com - October 10 at 8:37 AM
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific OfficerZafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
finance.yahoo.com - October 10 at 8:37 AM
When Will Zafgen Inc (ZFGN) Run Out Of Cash?When Will Zafgen Inc (ZFGN) Run Out Of Cash?
finance.yahoo.com - October 5 at 8:17 AM
Zafgen, Inc. (ZFGN) Given Consensus Recommendation of "Hold" by BrokeragesZafgen, Inc. (ZFGN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 1 at 2:20 PM
-$0.54 EPS Expected for Zafgen Inc (ZFGN) This Quarter-$0.54 EPS Expected for Zafgen Inc (ZFGN) This Quarter
www.americanbankingnews.com - September 28 at 8:28 AM
Zafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 DiabetesZafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
www.streetinsider.com - September 14 at 12:06 PM
Zafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes - StreetInsider.comZafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes - StreetInsider.com
www.streetinsider.com - September 13 at 1:42 AM
Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 DiabetesZafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
finance.yahoo.com - September 12 at 8:41 PM
Zafgen (ZFGN) Announces New Preclinical Data on ZGN-1061 - StreetInsider.comZafgen (ZFGN) Announces New Preclinical Data on ZGN-1061 - StreetInsider.com
www.streetinsider.com - September 12 at 12:38 PM
Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of DiabetesZafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
finance.yahoo.com - September 12 at 12:38 PM
Zafgen, Inc. (NASDAQ:ZFGN) Given Average Recommendation of "Hold" by AnalystsZafgen, Inc. (NASDAQ:ZFGN) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 12 at 5:02 PM
Q3 2017 EPS Estimates for Zafgen, Inc. Increased by Leerink Swann (ZFGN)Q3 2017 EPS Estimates for Zafgen, Inc. Increased by Leerink Swann (ZFGN)
www.americanbankingnews.com - August 11 at 7:48 AM
Zafgen, Inc. (ZFGN) Releases  Earnings Results, Beats Estimates By $0.03 EPSZafgen, Inc. (ZFGN) Releases Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 10 at 3:22 PM
Zafgen Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)Zafgen Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 3:29 PM
Investor Network: Zafgen, Inc. to Host Earnings CallInvestor Network: Zafgen, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 9:28 AM
Zafgen Reports Second Quarter 2017 Financial ResultsZafgen Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 9:28 AM
Zafgen reports 2Q lossZafgen reports 2Q loss
finance.yahoo.com - August 9 at 9:28 AM
Zafgen to Present at the Canaccord Genuity 37th Annual Growth ConferenceZafgen to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 9:13 AM
Zafgen to Host Conference Call to Discuss Second Quarter 2017 Financial ResultsZafgen to Host Conference Call to Discuss Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 9:03 AM
Zafgen, Inc. (ZFGN) Scheduled to Post Earnings on WednesdayZafgen, Inc. (ZFGN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:45 AM
Zafgen, Inc. (NASDAQ:ZFGN) Receives Consensus Rating of "Hold" from AnalystsZafgen, Inc. (NASDAQ:ZFGN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 18 at 5:31 PM
Zafgen, Inc. (NASDAQ:ZFGN) Short Interest UpdateZafgen, Inc. (NASDAQ:ZFGN) Short Interest Update
www.americanbankingnews.com - July 16 at 7:14 AM

SEC Filings

Zafgen (NASDAQ:ZFGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zafgen (NASDAQ:ZFGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zafgen (NASDAQ ZFGN) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.